Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
298.37(c) 299.42(c) 303.09(c) 298.11(c) 296.52 Last
492 494 646 331 548 042 692 740 608 965 Volume
+0.06% +0.35% +1.23% -1.64% -0.53% Change
More quotes
Financials (USD)
Sales 2019 7 346 M
EBIT 2019 2 153 M
Net income 2019 1 941 M
Finance 2019 5 385 M
Yield 2019 -
Sales 2020 8 006 M
EBIT 2020 2 710 M
Net income 2020 2 360 M
Finance 2020 7 010 M
Yield 2020 -
P/E ratio 2019 18,0x
P/E ratio 2020 14,8x
EV / Sales2019 3,67x
EV / Sales2020 3,17x
Capitalization 32 370 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.2%); - supply of collaborative services (32.6%): working with Sanofi... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
07/19REGENERON PHARMACEUTICALS : Statement Regarding Praluent® (alirocumab) in German..
PU
07/18REGENERON PHARMACEUTICALS : Announces the 2019 Winners of the Prize for Creative..
PR
07/11REGENERON PHARMACEUTICALS : Statement Regarding Düsseldorf Regional Court Decisi..
PU
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/08REGENERON PHARMACEUTICALS : to Report Second Quarter 2019 Financial and Operatin..
PR
07/02SANOFI : - Libtayo approved for advanced cutaneous squamous cell carcinoma in th..
AQ
07/02REGENERON PHARMACEUTICALS : Libtayo Approved for Advanced Cutaneous Squamous Cel..
AQ
07/01REGENERON PHARMACEUTICALS : Libtayo® (cemiplimab) Approved for Advanced Cutaneou..
PU
07/01REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Moderate-to..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
11:37aGILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
08:54aGILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 389,43  $
Last Close Price 296,52  $
Spread / Highest target 65,3%
Spread / Average Target 31,3%
Spread / Lowest Target 9,60%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-20.18%32 544
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS5.08%44 598
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372